I think a BRAF mutation drug is more likely, in all. The results coming out of the current BRAF trials are tremendous, however, mutations are developing. And, the indications (think: skin cancer) is a huge market for BRAF.
Hh, unless they show more effectiveness in other indications other than the two indications it REALLY works in, is going to remain a really small but highly effective drug. They need to show results in ligand disease....
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.